Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

Inspire completes studies prior to end-of-phase II meeting

Oct. 18, 2005

PDE3/4 inhibitors activate CFTR in a cell culture model

Oct. 17, 2005

Recent patents report new treatments for respiratory disorders

Oct. 13, 2005

Critical Therapeutics plans Zyflo launch

Oct. 11, 2005

New study raises the red flag for PDE4 inhibitors

Oct. 11, 2005

Phase III program begins for tobramycin inhalation powder in cystic fibrosis

Oct. 10, 2005

Recent patents cover novel agents for respiratory and other inflammatory disorders

Oct. 7, 2005

Evidence suggests the DP1 receptor may be a novel target for antiallergic therapies

Oct. 7, 2005

Anti-IL-13 antibody (CAT-354) effective against allergic airway and esophageal inflammation in mice

Oct. 5, 2005

Novel VLA-4 antagonist prevents pulmonary inflammation and airway hyperreactivity in vivo

Oct. 4, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...